Evaluation of treatment response and characteristics of cervical cancer patients treated with cisplatin based chemoradiotherapy with/without neoadjuvant chemotherapy with cisplatin and gemcitabin

• Grant number: 15/22125-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2015
• End date: November 30, 2016
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Maria Del Pilar Estevez Diz
• Grantee: Luísa de Oliveira Mestre
• Host Institution: Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP). Coordenadoria de Serviços de Saúde (CSS). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Cervical cancer is a public health issue not only in Brazil but in the whole World, due to the fact diagnosis being made by the time the illness is already locally advanced, for each patient in four. For about a decade, locally invasive cervical cancer's (LICC) standard treatment is Chemoradiation with platinating agents, several studies were made and there was further improvement to the treatment, among these it is worth noticing associating methods of Chemoradiation and Chemotherapy adjuvant, and also select neoadjuvant drugs. In both studies, survival and "progression-free survival" increases were observed. Furthermore, hypothesis suggests that "growth and angiogenic" factors, which "intermediate angiogenesis, tumoral growth and tumoral progression", vary quantitatively throughout the process, presenting themselves as indirect cues of tumoral progression.The main objective of this study is to evaluate the response rate of patients undergone Chemotherapy treatment with concomitant cisplatin, associated or not to neoadjuvant Chemotherapy. Secondary goals include characterizing the clinical and epidemiologic profile of the patients subject to this study, building and sorting a "sample library" to further evaluation of "angiogeneses, thrombogenesis and growth factors of these patients.The first 50 patients, included in the Phase II randomized trial, uni centrical, prospective, noncomparative, with patients, admitted in the Instituto do Câncer do Estado de São Paulo (ICESP), that were under the inclusion and exclusion criteria for the macro-study "Estudo de Fase II, prospectivo, randomizado, não comparativo, de tratamento com quimioterapia de indução com cisplatina e gencitabina seguida de quimioirradiação ou quimioirradiação definitiva em carcinomas invasivos da cérvice uterina localmente avançados", will be assessed. Response evaluation will be given by radiological exams according to the RECIST staging criteria in specific periods, and biomarkers evaluation will be done with blood samples from biopsy blocks already collected and stored; in this analysis will be used Angiopoietin-2 multiplex pannel, BMP-9, EGF, Endothelin-1, FGF-1, FGF-2, Follistatin, G-CSF, HB-EGF, HGF, IL-8, Leptin, PLGF, VEGF-A, VEGF-C, VEGF-D.